The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company's award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it is possible to restore the efficacy of approved antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening infections that emerged in recent years due to the resistance of bacterial strains against existing antibiotics. BioVersys' compounds will be used in combination with existing antibiotics, thereby renewing efficacy as well as intellectual property for the established drug. The current research focus is Nosocomial Infections (hospital acquired infections) and Tuberculosis. In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, BioVersys is developing a preclinical candidate for the treatment of multidrug-resistant tuberculosis.
Over the last three decades, the number of newly approved antibiotics has steadily declined. At the same time, resistance against existing drugs has become more and more prevalent. Antibiotic resistance is newly recognized by the WHO as a major public health concern as exemplified by its recently released global report (click HERE for access). BioVersys has a pipeline of promising compounds that address this concern. The company is currently at preclinical stage with proof-of-concept in animals already demonstrated.